Clomiphene

CLOMID labeling describes potentially prolonged or irreversible visual disturbances and calls for prompt ophthalmological assessment when visual symptoms occur. Its labeled use concerns ovulatory dysfunction; an enclomiphene trial cannot verify clomiphene-specific male recovery claims. A separate 2026 review of clomiphene's off-label use after anabolic-steroid exposure likewise found that its efficacy, safety and monitoring in that setting remain poorly defined.^[1][2]

• A label warning is not a precise incidence estimate; clomiphene and enclomiphene must be distinguished.
• The 2026 review is a narrative (non-systematic) review, abstract-checked only (full text paywalled); it describes the state of evidence rather than reporting new trial data.

A 2026 narrative review of clomiphene citrate's off-label use after anabolic-androgenic steroid cessation found that no standardized treatment exists and that clomiphene's clinical efficacy, safety and optimal monitoring strategy in that setting remain poorly defined. It reported that hormonal parameters often improve but symptomatic recovery varies, and that newer approaches, including the enclomiphene isomer, lack validation specifically in anabolic-steroid-induced hypogonadism populations.^[2]

• Narrative (non-systematic) review; abstract-checked only, full text paywalled.
• Describes the state of evidence and clinical practice patterns rather than reporting new trial data; does not itself establish or recommend any specific treatment approach.
• This finding documents an evidence gap; it is not a recommendation and should not be read as describing a validated or appropriate regimen.